



PHARMALENE® LDPE / Low density polyethylene bio attributed

FL 20 PH BA

MAIN APPLICATIONS

Pharmalene FL 20 PH BA is intended for the use within pharmaceutical sector and is characterized by an optimal balance between processability and mechanical properties.

Pharmalene FL 20 PH BA is suitable for the production of multilayer films for blisters and for pharmaceutical monodoses or small bottles.

PROCESSING NOTES

Pharmalene FL 20 PH BA can be processed by conventional blown film extrusion equipments. Melt temperature from 160 °C to 190°C is recommended. Depending on extrusion conditions, the suggested film thickness is 25+80 µm.

STORAGE AND HANDLING

Pharmalene FL 20 PH BA is supplied in pellet form. This material may readily be conveyed and bulk fed through equipment designed for conventional pelletised polyethylene resin, provided the equipment is designed to prevent accumulation of fines and dust particles that are contained in all polyethylene resins. These fines and dust particles can, under certain conditions, pose an explosion hazard. We recommend that the conveying system used, is equipped with filters of adequate size, operated and maintained in such a manner to ensure that no leaks develop and earthed adequately. We further recommend, that good housekeeping should be practised throughout your facility.

Shelf Life: Polyethylene can be stored over a long period of time, as long as it is stored protected from solar irradiation, in a ventilated, dry and cool place, with a temperature kept below 50°C. Any exposure of the material to solar irradiation, reinforced by higher temperatures, has a detrimental impact on the product quality and can induce a degradation, which goes on subsequently.

We guarantee that Versalis Pharmalene® products keep complying with Versalis sales specification for 2 years after date of delivery under the recommended storage conditions. This statement does not prevent user performing MFR and density tests on the incoming material and every year for quality evaluation.

Ensuring a consistent material quality, we strongly recommend to follow the above mentioned handling and storage conditions for all Pharmalene® products. In case of non-respect of these storage precautions, Versalis cannot be held liable to any quality problem related to inappropriate handling and storage of the material and shelf-life can be altered.

Before using this product it is recommended to refer to the relevant Safety Data Sheet (SDS) for more detailed information.

AVAILABILITY

Contact the Versalis sales office nearest to you regarding availability and your specific application requirements.

FOOD CONTACT AND PHARMACOPOEIA STATUS

Pharmalene FL 20 PH BA complies with the European Union (Reg. 10/2011) and the USA (FDA) rules, related to the use of plastic materials intended for contact with foodstuffs. The composition of our product is compliant to the relevant sections of the European Pharmacopoeia (10th ed.) and those of the U.S. Pharmacopoeia (USP 42). Certificates of compliance are available upon request.

TECHNICAL MANAGEMENT POLYETHYLENE

Versalis S.p.A.

Head Office
Piazza Boldrini, 1
20097 San Donato Milanese (MI) - Italy
tel. +39 02 52032998

Versalis Int. SA - Zweigniederlassung Deutschland

Duesseldorfer Str. 13
65760 Eschborn - Deutschland
tel. +49 15140260561

IMPORTANT: please consult the relevant safety data sheet for more detailed information. The information and data presented herein are to the best of our knowledge true and accurate but no warranty or guarantee, expressed or implied, is made nor is any liability accepted with respect to the use of such information and data. Versalis is available to provide the guaranteed values for each product on demand.

DISCLAIMER: It is the responsibility of the user to verify the technical suitability and the safe and regulatory compliant usage of this product in all medical and pharmaceutical applications. If a usage of this product in applications of the pharmaceutical and medical sector, such as Class I, IIa, IIb or III Medical Devices (U.S. FDA, Health Canada and/or EU Directive 2007/47/EC) and in applications involving permanent implantation into the human body, is intended, user must consult Versalis to receive prior written approval for each specific product and applications.